Seres Therapeutics Files 8-K on Operations and Financials
Ticker: MCRB · Form: 8-K · Filed: Jan 10, 2025 · CIK: 1609809
| Field | Detail |
|---|---|
| Company | Seres Therapeutics, Inc. (MCRB) |
| Form Type | 8-K |
| Filed Date | Jan 10, 2025 |
| Risk Level | low |
| Pages | 5 |
| Reading Time | 6 min |
| Key Dollar Amounts | $0.001, $31 million, $75 million |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, financials, operations
TL;DR
Seres Therapeutics dropped an 8-K on Jan 9th covering ops and financials.
AI Summary
On January 9, 2025, Seres Therapeutics, Inc. filed an 8-K report detailing results of operations and financial condition, along with other events and financial statements. The company, incorporated in Delaware with its principal executive offices in Cambridge, MA, previously operated under the name Seres Health, Inc. before changing its name on June 3, 2014.
Why It Matters
This filing provides an update on Seres Therapeutics' operational and financial status, which is crucial for investors to assess the company's performance and future prospects.
Risk Assessment
Risk Level: low — This is a routine filing of an 8-K report, which typically contains standard corporate information and does not indicate any immediate or significant new risks.
Key Players & Entities
- Seres Therapeutics, Inc. (company) — Registrant
- January 9, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- Cambridge, MA (location) — Address of principal executive offices
- Seres Health, Inc. (company) — Former company name
- June 3, 2014 (date) — Date of name change
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report on the Results of Operations and Financial Condition, Other Events, and Financial Statements and Exhibits of Seres Therapeutics, Inc.
When was the earliest event reported in this filing?
The earliest event reported in this filing occurred on January 9, 2025.
In which state is Seres Therapeutics, Inc. incorporated?
Seres Therapeutics, Inc. is incorporated in Delaware.
What is the principal executive office address for Seres Therapeutics, Inc.?
The principal executive office address for Seres Therapeutics, Inc. is 101 Cambridgepark Drive, Cambridge, MA 02140.
What was the former name of Seres Therapeutics, Inc. and when did the name change occur?
The former name of Seres Therapeutics, Inc. was Seres Health, Inc., and the name change occurred on June 3, 2014.
Filing Stats: 1,398 words · 6 min read · ~5 pages · Grade level 14.1 · Accepted 2025-01-10 07:00:18
Key Financial Figures
- $0.001 — ich registered Common stock, par value $0.001 per share MCRB The Nasdaq Stock Mar
- $31 million — n preliminary financial results, it had $31 million in cash and cash equivalents (unaudited
- $75 million — y and July 2025 (totaling approximately $75 million) related to the VOWST sale, transaction
Filing Documents
- d925391d8k.htm (8-K) — 33KB
- d925391dex991.htm (EX-99.1) — 22KB
- 0001193125-25-004062.txt ( ) — 182KB
- mcrb-20250109.xsd (EX-101.SCH) — 3KB
- mcrb-20250109_lab.xml (EX-101.LAB) — 17KB
- mcrb-20250109_pre.xml (EX-101.PRE) — 11KB
- d925391d8k_htm.xml (XML) — 3KB
Forward-Looking Statements
Forward-Looking Statements This Current Report contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this Current Report that do not relate to matters of historical fact should be considered forward-looking statements, including statements about: our anticipated financial performance, including cash and cash equivalents, for any period of time, including for the year ended December 31, 2024; the timing and results of our clinical studies and data readouts; our clinical development plans; the potential market for SER-155 and other product candidates, if approved; the projected cash runway; and other statements which are not historical fact. These forward-looking statements are based on management's current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the important factors discussed under the caption "Risk Factors" in our Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the "SEC"), on November 13, 2024, and our other reports filed with the SEC could cause actual results to differ materially from those indicated by the forward-looking statements made in this Current Report. Any such forward-looking statements represent management's estimates as of the date of this Current Report. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this Current Report. Financial Disclosure
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. The following Exhibit 99.1 relates to Item 2.02, and shall be deemed to be furnished, and not filed: Exhibit No. Description 99.1 Seres Therapeutics, Inc. Translational Biomarker Results from SER-155 Phase 1b Clinical Study Press Release as of January 9, 2025 104 Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: January 10, 2025 SERES THERAPEUTICS, INC. By: /s/ Thomas J. DesRosier Name: Thomas J. DesRosier Title: Chief Legal Officer and Executive Vice President